Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | PPARD | Q03181 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.39 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334260 | 0.89 | PPARD (0.55) | NPC1RAB9APPARGPPARDPPARA | |
| SCHEMBL334141 | 0.87 | PPARG (0.48) | NPC1RAB9APPARGPPARDPPARA | |
| SCHEMBL10271969 | 0.87 | PPARG (0.47) | NPC1RAB9APPARGPPARDPPARA | |
| SCHEMBL4638656 | 0.86 | PPARD (0.49) | NPC1RAB9APPARGPPARDPPARA | |
| SCHEMBL10221031 | 0.84 | PPARD (0.58) | NPC1RAB9APPARGPPARDPPARA | |
| SCHEMBL10271164 | 0.82 | PPARD (0.54) | PPARGPPARDPPARATP53SMN1; SMN2 | |
| SCHEMBL10221018 | 0.81 | PPARD (0.58) | NPC1RAB9APPARGPPARDPPARA | |
| SCHEMBL10221055 | 0.79 | PPARD (0.67) | PPARGPPARDPPARA | |
| SCHEMBL335794 | 0.76 | PPARD (0.62) | NPC1RAB9APPARGPPARDPPARA | |
| SCHEMBL10221019 | 0.76 | PPARD (0.59) | PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | NPC1 1742/4885RAB9A 1784/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.